Tekla Capital Management LLC Acadia Pharmaceuticals Inc Transaction History

Tekla Capital Management LLC

11 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$16.79 - $27.09 $1.21 Million - $1.96 Million	72,225 New	72,225 $1.69 Million
Q3 2021 Nov 12, 2021	SELL	$15.78 - $24.77 $5.24 Million - $8.22 Million	-331,789 Closed	0 $0
Q4 2020 Feb 12, 2021	BUY	$41.04 - $56.79 $3.33 Million - $4.6 Million	81,046 Added 32.32%	331,789 $17.7 Million
Q2 2020 Aug 13, 2020	BUY	$39.26 - $52.73 $1.14 Million - $1.54 Million	29,144 Added 13.15%	250,743 $12.2 Million
Q1 2020 May 14, 2020	BUY	$31.65 - $46.87 $104,951 - $155,420	3,316 Added 1.52%	221,599 $9.36 Million
Q4 2019 Feb 13, 2020	BUY	$36.21 - $51.4 $2.11 Million - $2.99 Million	58,136 Added 36.3%	218,283 $9.34 Million
Q2 2019 Aug 14, 2019	BUY	$23.32 - $28.12 $1.29 Million - $1.56 Million	55,433 Added 52.94%	160,147 $4.28 Million
Q1 2019 May 14, 2019	BUY	$16.17 - $27.38 $1.69 Million - $2.87 Million	104,714 New	104,714 $2.81 Million
Q4 2018 Feb 13, 2019	SELL	$14.32 - $22.92 $1.34 Million - $2.15 Million	-93,689 Closed	0 $0
Q1 2018 May 14, 2018	SELL	$22.47 - $32.33 $3.42 Million - $4.92 Million	-152,196 Reduced 61.9%	93,689 $2.11 Million
Q4 2017 Feb 14, 2018	BUY	$26.84 - $39.14 $6.6 Million - $9.62 Million	245,885	245,885 $7.4 Million

279

156M

901K

314K

Ticker ACAD
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 161,843,008
Market Cap $2.76B
Description
ACADIA Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of small molecule drugs that address unmet medical needs in central nervous system disorders. The company offers NUPLAZID (pimavanserin) for the treatment of hallucinations and delusions associated with Parkinson's disease psychosis. It's p...

Get notified when there are updates to the investment portfolio of Tekla Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Tekla Capital Management LLC with notifications on news.